Monitoring antiangiogenesis of bevacizumab in zebrafish
نویسندگان
چکیده
منابع مشابه
Macrocyclic glycohybrid toolbox identifies novel antiangiogenesis agents from zebrafish assay.
A practical and modular approach to obtain a diverse set of 14-membered macrocyclic compounds from carbohydrates is developed that utilizes functional groups at C-1 and C-5. The evaluation of this toolbox in various zebrafish assays led to the identification of 2.7f as an antiangiogenesis agent.
متن کاملcomprehension monitoring in l1&l2
هدف اصلی این تحقیق مقایسه و تمایز بین روشها و استراتژیهای خاص برای درک مطلب بهتر در زبان مادری و زبان دوم بوده است. در قدم اول میزان توانایی افراد در درک مطلب فارسی و انگلیسی اندازه گیری و سپس رده بندی شد. همچنین از دانش آموزان خواسته شد که در مورد روشها و استراتژیهایی که برای درک مطلب بهتر به کار برده بودند توضیح دهند. نتیجه این مرحله از تحقیق نشان داد که دانشجویان برای درک مطلب مطلوب در زبان ...
15 صفحه اولBlood pressure monitoring in patients receiving bevacizumab.
We have read with great interest the prospective study by Shah et al. [1] assessing the safety of short infusions of bevacizumab. The authors report similar rates of proteinuria and hypertension in patients receiving the standard infusion regimen (over 90, 60 then 30 min), compared with shorter administrations with an infusion rate of 0.5 mg/kg/min. Although we agree with Shah et al. that short...
متن کاملAntiangiogenesis in haematological malignancies.
Angiogenesis, the growth of new capillary blood vessels, is a central regulator of cancer growth, and a validated target for cancer therapy. The antiangiogenic agents in clinical use target one or more cellular pathways involved in the cascade of vascular growth. In haematological malignancies, angiogenesis occurs within a bone marrow ecosystem comprised of closely apposed malignant cells, endo...
متن کاملMonitoring Monoclonal Antibody Delivery in Oncology: The Example of Bevacizumab
Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied with monoclonal antibodies. As a consequence, the efficacy or side effects associated with this type of treatment often appear to be sporadic. Bevacizumab is...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Design, Development and Therapy
سال: 2018
ISSN: 1177-8881
DOI: 10.2147/dddt.s166330